Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). METHODS: We conducted a phase 2, single-cohort, 25-center, global study of tisagenlecleucel in pediatric and young adult patients with CD19+ relapsed or refractory B-cell ALL. The primary end point was the overall remission rate (the rate of complete remission or complete remission with incomplete hematologic recovery) within 3 months. RESULTS: For this planned analysis, 75 patients received an infusion of tisagenlecleucel and could be evaluated for efficacy. The overall remission rate within 3 months was 81%, with all patients who had a response to treatment found to be negative for minimal residual disease, as assessed by means of flow cytometry. The rates of event-free survival and overall survival were 73% (95% confidence interval [CI], 60 to 82) and 90% (95% CI, 81 to 95), respectively, at 6 months and 50% (95% CI, 35 to 64) and 76% (95% CI, 63 to 86) at 12 months. The median duration of remission was not reached. Persistence of tisagenlecleucel in the blood was observed for as long as 20 months. Grade 3 or 4 adverse events that were suspected to be related to tisagenlecleucel occurred in 73% of patients. The cytokine release syndrome occurred in 77% of patients, 48% of whom received tocilizumab. Neurologic events occurred in 40% of patients and were managed with supportive care, and no cerebral edema was reported. CONCLUSIONS: In this global study of CAR T-cell therapy, a single infusion of tisagenlecleucel provided durable remission with long-term persistence in pediatric and young adult patients with relapsed or refractory B-cell ALL, with transient high-grade toxic effects. (Funded by Novartis Pharmaceuticals; ClinicalTrials.gov number, NCT02435849 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some immunotherapies have shown promise in this setting, such as dinutuximab administered in combination with cytotoxic therapy in relapsed/refractory neuroblastoma3,4.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“It has been reported that CAR-T cell therapy shows high response rates to B-ALL patients in different age groups [117–119].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“Any grade 3 or 4 adverse event 19 (25) 33 (44) 8 (11) 4 (6)”
Self-citationLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Self-citationMilone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197 · cited 2×
“Increase in aspartate aminotransferase 5 (7) 2 (3) — —”
BackgroundSelf-citationGardner, R. A., Finney, O., Annesley, C., Brakke, H., Summers, C., Leger, K., Bleakley, M., Brown, C., Mgebroff, S., Kelly-Spratt, K. S., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769208 · Cited by 1,121
von Stackelberg, A., Locatelli, F., Zugmaier, G., Handgretinger, R., Trippett, T. M., Rizzari, C., Bader, P., O’Brien, M. M., Brethon, B., Bhojwani, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3301 · Cited by 614 · cited 1×
“Decrease in neutrophil count 1 (1) 6 (8) 1 (1) 1 (1)”
Self-citationSabatino, M., Hu, J., Sommariva, M., Gautam, S., Fellowes, V., Hocker, J. D., Dougherty, S., Qin, H., Klebanoff, C. A., Fry, T. J., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683847 · Cited by 383
Cited by
Items 901–1,000 of 1,024
Honing CAR T cells to tackle acute myeloid leukemia
Haubner, S., Subklewe, M., & Sadelain, M. (2024) · Blood · doi:10.1182/blood.2024024063 · Cited by 77
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
Köksal, H., Dillard, P., Josefsson, S. E., Maggadottir, S. M., Pollmann, S., Fåne, A., Blaker, Y. N., Beiske, K., Huse, K., Kolstad, A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018029678 · Cited by 65
Frigault, M. J., Nikiforow, S., Mansour, M. K., Hu, Z., Horowitz, M. M., Riches, M., Hematti, P., Turtle, C. J., Zhang, M., Perales, M., et al. (2020) · Blood · doi:10.1182/blood.2020006216 · Cited by 70
Liu, E., Ang, S., Kerbauy, L. N., Başar, R., Kaur, I., Kaplan, M., Li, L., Tong, Y., Daher, M., Ensley, E. L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626098 · Cited by 75
“Transient retroviral supernatants were produced as previously described (1).”
BackgroundMethodInfluentialBalancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments
Geethakumari, P. R., Ramasamy, D. P., Dholaria, B., Berdeja, J. G., & Kansagra, A. J. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00635-3 · Cited by 70
Short, N. J., Kantarjian, H. M., & Jabbour, E. J. (2021) · Leukemia · doi:10.1038/s41375-021-01277-3 · Cited by 68
Idecabtagene Vicleucel (ide-cel) CAR T-cell Therapy for Relapsed and Refractory Multiple Myeloma
Anderson, L. D. (2021) · Future Oncology · doi:10.2217/fon-2021-1090 · Cited by 72
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure
Wachsmann, T. L. A., Wouters, A. K., Remst, D. F. G., Hagedoorn, R. S., Meeuwsen, M. H., van Diest, E., Leusen, J. H. W., Kuball, J. H. E., Falkenburg, J. H. F., & Heemskerk, M. H. M. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2033528 · Cited by 72
“Furthermore, a substantial fraction of patients eventually suffer from relapse.(5,6) These relapses can include not only antigennegative relapses but also antigen-positive relapses, indicating low CAR T cell persistence or incomplete clearance of tumor cells due to CAR T cell dysfunction.”
BackgroundZhou, W., Lei, S., Liu, M., Li, D., Huang, Y., Hu, X., Yang, J., Li, J., Fu, M., Zhang, M., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121872 · Cited by 67
Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
Kilgour, M. K., Bastin, D. J., Lee, S., Ardolino, M., McComb, S., & Visram, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1166038 · Cited by 72
“Loss of target antigen on tumor cells is an obvious mechanism by which CAR-T therapies fail (108, 109).”
BackgroundMunir, F., Hardit, V., Sheikh, I. N., Alqahtani, S., He, J., Cuglievan, B., Hosing, C. M., Tewari, P., & Khazal, S. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210095 · Cited by 78
“Anti-CD19 CAR T-cell therapy is a groundbreaking innovation to combat R/R hematological malignancies, most commonly pediatric acute lymphoblastic leukemia [203].”
BackgroundEngineering strategies to safely drive CAR T-cells into the future
Rossi, M., & Breman, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1411393 · Cited by 73
“Despite the unprecedented responses obtained with CAR T-cell therapies in hematological malignancies (102 – 107), these initial successes did not translate into other indications, and results in solid tumors have been especially underwhelming (108, 109).”
BackgroundNovel strategies to manage CAR-T cell toxicity
Mulvey, A., Trueb, L., Coukos, G., & Arber, C. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01100-5 · Cited by 72
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 78
Aamir, S., Anwar, M. Y., Khalid, F., Khan, S. I., Ali, M. A., & Khattak, Z. E. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.12.010 · Cited by 66
Non-viral transfection technologies for next-generation therapeutic T cell engineering
Raes, L., Smedt, S. C. D., Raemdonck, K., & Braeckmans, K. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107760 · Cited by 69
Wu, J., Meng, F., Cao, Y., Zhang, Y., Zhu, X., Wang, N., Wang, J., Huang, L., Zhou, J., & Xiao, Y. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00523-2 · Cited by 69
Self-citationMcNerney, K. O., DiNofia, A. M., Teachey, D. T., Grupp, S. A., & Maude, S. L. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0203 · Cited by 75
Self-citationDesign considerations for early-phase clinical trials of immune-oncology agents
Wages, N. A., Chiuzan, C. C., & Panageas, K. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0389-8 · Cited by 69
“In 2017, based on a pivotal Phase II trial, the FDA approved the first chimeric antigen receptor (CAR-T) cell therapy (tisagenlecleucel) for children and young adults with B-cell ALL in a population with limited treatment and poor outcomes [58].”
BackgroundMohty, M., Gauthier, J., Malard, F., Aljurf, M. D., Bazarbachi, A. A., Chabannon, C., Kharfan‐Dabaja, M. A., Savani, B. N., Huang, H., Kenderian, S. S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0615-5 · Cited by 67
Roex, G., Feys, T., Beguin, Y. P., Kerre, T. C. C., Poiré, X., Lewalle, P., Vandenberghe, P., Bron, D., & Anguille, S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020194 · Cited by 71
“The phase II ELIANA trial investigated the CD19-directed genetically modified autologous T-cell product tisa-cel as a single infusion for r/r pediatric and young adult B-cell ALL [31].”
BackgroundInfluentialAldoss, I. T., Otoukesh, S., Zhang, J., Mokhtari, S., Ngo, D., Mojtahedzadeh, M., Malki, M. M. A., Salhotra, A., Ali, H., Aribi, A. M., et al. (2021) · Cancer · doi:10.1002/cncr.33967 · Cited by 65
“547 MRD 7 (18) 7 (14) r/r 31 (82) 44 (86) Blast % before blinatumomab,”
Barbar, T., & Sathick, I. J. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.09.007 · Cited by 75
Talleur, A. C., Qudeimat, A., Métais, J., Langfitt, D. M., Mamcarz, E. K., Crawford, J. C., Huang, S., Cheng, C., Hurley, C., Madden, R. M., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006293 · Cited by 67
Yan, X., Chen, D., Wang, Y., Guo, Y., Tong, C., Wei, J., Zhang, Y., Wu, Z., & Han, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00915-1 · Cited by 67
“However, despite these encouraging advancements, ~20% of CD19 R/R B-cell ALL patients who received an infusion of CD19 CAR T cells had no complete remission within 3 months, and approximately 50% of patients relapsed within a year.(9) Hence, the key challenge is uncovering the underlying resistance mechanisms to CAR T…”
BackgroundSelf-citationPal, S. K., Miller, M. J., Agarwal, N., Chang, S. M., Chávez‐MacGregor, M., Cohen, E. E. W., Cole, S., Dale, W., Diefenbach, C., Disis, M. L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02037 · Cited by 77
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
Donnadieu, E., Luu, M., Alb, M., Anliker, B., Arcangeli, S., Bonini, C., Angelis, B. D., Choudhary, R., Espie, D., Galy, A. H. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003486 · Cited by 69
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia
Moskop, A. M., Pommert, L., Baggott, C., Prabhu, S., Pacenta, H. L., Phillips, C. L., Rossoff, J. E., Stefanski, H. E., Talano, J., Margossian, S. P., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006393 · Cited by 71
“Tisagenlecleucel (KYMRIAH, Novartis), a CD19-directed CART, was US Food and Drug Administration approved in August 2017 for treatment of relapsed/refractory (R/R) B-ALL and is commercially available to patients up to age 25 years.(9-12) The ELIANA trial excluded patients younger than age 3 years; therefore, the publis…”
MethodSelf-citationCAR T Cell Locomotion in Solid Tumor Microenvironment
Nguyen, D., Ogando‐Rivas, E., Liu, R., Wang, T., Rubin, J. A., Jin, L., Tao, H., Sawyer, W. W., Méndez‐Gómez, H. R., Cascio, M., et al. (2022) · Cells · doi:10.3390/cells11121974 · Cited by 69
Cortés-López, M., Schulz, L., Enculescu, M., Paret, C., Spiekermann, B., Quesnel-Vallières, M., Torres-Diz, M., Unic, S., Busch, A., Orekhova, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31818-y · Cited by 67
Aldoss, I. T., Khaled, S. K., Wang, X., Palmer, J. M., Wang, Y., Wagner, J. R., Clark, M. C., Simpson, J., Paul, J. A., Vyas, V., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2038 · Cited by 67
Bader, P., Rössig, C., Hutter, M., Ayuk, F. A., Baldus, C. D., Bücklein, V., Bonig, H. B., Cario, G., Einsele, H., Holtick, U., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008981 · Cited by 65
“13 JUNE 2023 • VOLUME 7, NUMBER 11 offered to the participating centers, and as in the real-world scenario, many centers are approved to treat patients after appropriate training.(10,11) Given the particular risk profile of the patients treated in the study presented, the overall response rate at day +28 of 87.”
Self-citationLi, N., Quan, A., Li, D., Pan, J., Ren, H., Hoeltzel, G. D., de Val, N., Ashworth, D., Ni, W., Zhou, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37616-4 · Cited by 69
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy
Hughes, A. D., Teachey, D. T., & Diorio, C. J. (2024) · Seminars in Immunopathology · doi:10.1007/s00281-024-01013-w · Cited by 76
“Treatment regimens for ICANS (Table 2) are less well established than those for CRS. Tocilizumab is not effective for the treatment of ICANS [11, 25, 104], possibly because tocilizumab, similar to other monoclonal antibodies, does not readily cross the BBB [105].”
BackgroundNovel Approaches to Acute Myeloid Leukemia Immunotherapy
Beyar‐Katz, O., & Gill, S. I. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3016 · Cited by 67
“In this context, a preclinical study showed that blockade of the PD-1/PD-L1 interaction augmented killing of AML blasts by AMG-330 (37), suggesting that BiTE or even CART shouldbe tested in combinationwithPD-1blockade (as is already being done in B-ALL).”
BackgroundInfluentialCAR T-cell immunotherapy of B-cell malignancy: the story so far
Halim, L., & Maher, J. F. (2020) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/2515135520927164 · Cited by 72
Bunse, M., Pfeilschifter, J. M., Bluhm, J., Zschummel, M., Joedicke, J. J., Wirges, A., Stark, H., Kretschmer, V., Chmielewski, M. M., Uckert, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20488-3 · Cited by 69
Goto, S., Sakoda, Y., Adachi, K., Sekido, Y., Yano, S., Eto, M., & Tamada, K. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02853-3 · Cited by 73
Therapeutic cancer vaccines revamping: technology advancements and pitfalls
Antonarelli, G., Corti, C., Tarantino, P., Ascione, L., Cortés, J., Romero, P. J., Mittendorf, E., Disis, M. L., & Curigliano, G. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2153 · Cited by 66
Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages
Ebrahimiyan, H., Tamimi, A., Shokoohian, B., Minaei, N., Memarnejadian, A., Hossein‐Khannazer, N., Hassan, M., & Vosough, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108587 · Cited by 69
CAR-T cell therapy: Where are we now, and where are we heading?
Wang, J., & Wang, L. (2023) · Blood Science · doi:10.1097/bs9.0000000000000173 · Cited by 71
CAR-T cell therapy for hematological malignancies: History, status and promise
Wang, C., Wang, J., Che, S., & Hai, Z. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21776 · Cited by 80
Ohno, R., & Nakamura, A. (2024) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2024.152479 · Cited by 67
Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics
McCloskey, C. W., Rodriguez, G. M., Galpin, K. J. C., & Vanderhyden, B. C. (2018) · Cancers · doi:10.3390/cancers10080244 · Cited by 67
“Food and Drug Administration has approved the use of several immune checkpoint inhibitors for non-small-cell lung cancer (NSCLC), melanoma, bladder cancer, renal cell carcinomas, and Hodgkin lymphoma and recently approved the first chimeric antigen receptor (CAR)-T-cell therapy to treat children with B-cell acute lymp…”
BackgroundImmune-Based Therapies in Acute Leukemia
Witkowski, M. T., Lasry, A., Carroll, W. L., & Aifantis, I. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.07.009 · Cited by 69
“Early trials in B-ALL therapy utilized “second-generation” CAR constructs, such as FDAapproved ‘Tisagenlecleucel’, whereby autologous T cells are transduced with lentiviral vectors expressing a CAR comprised of single-chain fragment (scFv) from a murine monoclonal antibody specific for CD19, a CD3-zeta domain for T-ce…”
MethodTransposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?
Magnani, C. F., Tettamanti, S., Alberti, G., Pisani, I., Biondi, A., Serafini, M., & Gaipa, G. (2020) · Cells · doi:10.3390/cells9061337 · Cited by 68
Gene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development
Massaro, G., Geard, A. F., Liu, W., Coombe-Tennant, O., Waddington, S. N., Baruteau, J., Gissen, P., & Rahim, A. A. (2021) · Biomolecules · doi:10.3390/biom11040611 · Cited by 68
“Lentivirus vectors have been used with resounding success clinically in ex vivo gene therapy, for example, in the treatment of primary immune deficiencies [47] and as an anti-cancer therapy in the generation of CAR T-cells [48].”
MethodCSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges
Harrer, D. C., Dörrie, J., & Schaft, N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235942 · Cited by 69
Alzubi, J., Dettmer‐Monaco, V., Kuehle, J., Thorausch, N., Seidl, M., Taromi, S., Schamel, W. W. A., Zeiser, R., Abken, H., Cathomen, T., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.06.014 · Cited by 67
“Both CD28- and 4-1BB-based CAR T cells showed promising clinical results against B cell malignancies, albeit with different tumor-killing kinetics: inclusion of CD28 appears to mediate faster tumor reduction, whereas 4-1BB promotes T cell persistence.(4,5,38) Our results are in line with these studies for lymphoid mal…”
BackgroundResultKo, A. H., Jordan, A. C., Tooker, E., Lacey, S. F., Chang, R. B., Li, Y., Venook, A. P., Tempero, M. A., Damon, L. E., Fong, L. H., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.07.017 · Cited by 68
Self-citationThe antigen‐binding moiety in the driver's seat of CARs
Hanssens, H., Meeus, F., De Veirman, K., Breckpot, K., & Devoogdt, N. (2022) · Medicinal Research Reviews · doi:10.1002/med.21818 · Cited by 60
“Indeed, blood persistence of Kymriah® has been shown months to years after infusion.(38,45,90) Owing to the availability of well‐characterized mAbs against a broad range of relevant target antigens, as well as to the initial idea behind the CAR concept, most CARs that are being developed are (murine) scFv‐based.”
BackgroundBCMA in Multiple Myeloma—A Promising Key to Therapy
Kleber, M., Ntanasis‐Stathopoulos, I., & Terpos, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184088 · Cited by 64
Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
Nixdorf, D., Sponheimer, M., Berghammer, D., Engert, F., Bader, U., Philipp, N., Pasikhani, M. K., Straub, T., Rohrbacher, L., Wange, L. E., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01905-0 · Cited by 70
Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors
Zhong, W., Xiao, Z., Qin, Z., Yang, J., Wen, Y., Yu, Z., Li, Y., Sheppard, N. C., Fuchs, S. Y., Xu, X., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2220 · Cited by 66
Self-citationKampouri, E., Ibrahimi, S. S., Xie, H., Wong, E. R., Hecht, J., Sekhon, M. K., Vo, A., Stevens‐Ayers, T., Green, D. J., Gauthier, J., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad708 · Cited by 68
“Chimeric antigen receptor (CAR)–modified T-cell immuno-therapy (CARTx) has revolutionized the management of B-cell and plasma cell malignancies, including B-cell acute lymphoblastic leukemia (ALL) [1, 2], non-Hodgkin lymphoma [3–7], and multiple myeloma [8–10].”
BackgroundCottrell, T. R., Lotze, M. T., Ali, A., Bifulco, C. B., Capitini, C. M., Chow, L. Q. M., Cillo, A. R., Collyar, D. E., Cope, L., Deutsch, J. S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010928 · Cited by 69
“18 205 Loss of B cell aplasia is highly associated with relapse.”
Taking a “BiTE out of ALL”: blinatumomab approval for MRD-positive ALL
Curran, E. K., & Stock, W. (2019) · Blood · doi:10.1182/blood-2018-12-852376 · Cited by 63
Azole antifungals and new targeted therapies for hematological malignancy
Lindsay, J., Teh, B. W., Micklethwaite, K. P., & Slavin, M. A. (2019) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000611 · Cited by 67
A Hydrogel-Integrated Culture Device to Interrogate T Cell Activation with Physicochemical Cues
Chin, M. H. W., Norman, M. D. A., Gentleman, E., Coppens, M.-O., & Day, R. M. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c16478 · Cited by 58
Xu, X., Huang, S., Xiao, X., Sun, Q., Liang, X., Chen, S., Zhao, Z., Huo, Z., Tu, S., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.569117 · Cited by 67
“It was found in clinical studies that 4-1BB–based CAR T-cells have greater persistence than CD28-based CAR Tcells (5, 8, 114).”
BackgroundInfluentialPrecision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics
Advani, D., Sharma, S., Kumari, S., Ambasta, R. K., & Kumar, P. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210308101029 · Cited by 71
Faude, S., Wei, J. M., Muralidharan, K., Xu, X., Wertheim, G. B. W., Paessler, M. E., Bhoj, V. G., Grupp, S. A., Maude, S. L., Rheingold, S. R., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004038 · Cited by 66
“However, a subset of patients eventually relapse with CD19(2) or CD19(1) leukemia, despite the initial response.(4,8,9) Loss of CD19 is due to escape mechanisms under CAR T-cell pressure, whereas CD19(1) relapse is attributable to loss of CAR T-cell function.”
BackgroundSelf-citationCAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions
Gill, S. I., & Brudno, J. N. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320085 · Cited by 75
Peinelt, A., Bremm, M., Kreyenberg, H., Cappel, C., Banisharif-Dehkordi, J., Erben, S., Rettinger, E., Jarisch, A., Meisel, R., Schlegel, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830773 · Cited by 70
Self-citationJin, C., Ma, J., Ramachandran, M., Yu, D., & Essand, M. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00875-5 · Cited by 60
Brog, R. A., Ferry, S. L., Schiebout, C. T., Messier, C. M., Cook, W. J., Abdullah, L., Zou, J., Kumar, P., Sentman, C. L., Frost, H. R., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0536 · Cited by 69
de-Souza-Ferreira, M., Ferreira, É. E., & de‐Freitas‐Junior, J. C. M. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00770-4 · Cited by 70
GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes
Uenishi, G. I., Repic, M., Yam, J. Y., Landuyt, A. E., Lakshmi, P. S., Guo, T., Zarin, P., Sassone‐Corsi, M., Chicoine, A. T., Kellogg, H., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.171844 · Cited by 72
“The past decade of drug development has been marked by exponential growth in cell therapies, with multiple regulatory approvals in oncology (1–4) establishing the foundation for clinical evaluation of new cell therapies for other disorders, including autoimmune and autoinflammatory diseases.”
BackgroundSelf-citationInnate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy
Li, C., Yu, X., Han, X., Chen, L., Wang, Z., Shao, S., Shao, F., Wang, H., Ma, S., & Liu, J. (2024) · iScience · doi:10.1016/j.isci.2024.110750 · Cited by 81
“168,169 However, elevated off-target risks, solid tumor physical barriers, and immunosuppressive TME lead to the poorer performance of CAR-T cell therapy in treating solid tumors.”
BackgroundAleksandrova, K., Leise, J., Priesner, C., Melk, A., Kubaink, F., Abken, H., Hombach, A., Aktas, M., Essl, M., Bürger, I., et al. (2019) · Transfusion Medicine and Hemotherapy · doi:10.1159/000495772 · Cited by 61
Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia
Merli, P., Algeri, M., Bufalo, F. D., & Locatelli, F. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00502-2 · Cited by 62
Song, M.-K., Park, B.-B., & Uhm, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205010 · Cited by 64
“6%) went on to develop the antigen-negative or partially negative relapse [11].”
BackgroundResultInfluentialCAR T cells and checkpoint inhibition for the treatment of glioblastoma
Shen, S. H., Woroniecka, K. I., Barbour, A. B., Fecci, P. E., Sanchez-Perez, L. A., & Sampson, J. H. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1727436 · Cited by 66
“In 2017, the FDA approved Article highlights ● The current standard-of-care regimen for glioblastoma using resection, radiotherapy, and chemotherapy only modestly improves survival in patients due to its inability to effectively eradicate all malignant cells ● Chimeric antigen receptor T cell therapy is highly effecti…”
BackgroundProspects and challenges for use of CAR T cell therapies in solid tumors
Ramakrishna, S., Barsan, V. V., & Mackall, C. L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1738378 · Cited by 68
Expanding Access to Chimeric Antigen Receptor T-Cell Therapies: Challenges and Opportunities
Kansagra, A. J., Farnia, S. H., & Majhail, N. S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279151 · Cited by 74
Buechner, J., Grupp, S. A., Hiramatsu, H., Teachey, D. T., Rives, S., Laetsch, T. W., Yanik, G. A., Wood, P. A., Awasthi, R., Yi, L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002757 · Cited by 66
“Median (min-max) 7 (0-17) 6 (1-19) 8 (0-17) 9 (1-21) 8 (0-21)”
Self-citationRagoonanan, D. S., Khazal, S. J., Abdel‐Azim, H., McCall, D. C., Cuglievan, B., Tambaro, F. P., Ahmad, A. H., Rowan, C. M., Gutiérrez, C., Schadler, K., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00474-4 · Cited by 64
Self-citationDiorio, C., Shaw, P. A., Pequignot, E., Orlenko, A., Chen, F., Aplenc, R., Barrett, D. M., Bassiri, H., Behrens, E., DiNofia, A. M., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002592 · Cited by 61
Self-citationNo free rides: management of toxicities of novel immunotherapies in ALL, including financial
Jain, T., & Litzow, M. R. (2018) · Hematology · doi:10.1182/asheducation-2018.1.25 · Cited by 66
“Corticosteroids are the mainstay in the absence of CRS, whereas tocilizumab is recommended if there is concurrent CRS.60 If mental status changes persist or worsening headache is noted, assessment of intracranial tension (fundoscopy) is recommended.”
BackgroundMethodInfluentialTreatment of relapsed/refractory paediatric aggressive B‐cell non‐Hodgkin lymphoma
Moleti, M. L., Testi, A. M., & Foà, R. (2020) · British Journal of Haematology · doi:10.1111/bjh.16461 · Cited by 62
“So far, the only reported paediatric experience with InO is in r/r ALL.”
BackgroundInfluentialEmerging Roles of 1D Vertical Nanostructures in Orchestrating Immune Cell Functions
Chen, Y., Wang, J., Li, X., Hu, N., Voelcker, N. H., Xie, X., & Elnathan, R. (2020) · Advanced Materials · doi:10.1002/adma.202001668 · Cited by 63
Glioma Stem Cells as Immunotherapeutic Targets: Advancements and Challenges
Piper, K. J., DePledge, L., Karsy, M. J., & Cobbs, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.615704 · Cited by 80
“Though CAR T cell therapies have been successful treating blood cancers — two different therapies were approved by the FDA in 2017 for treatment of acute lymphoblastic leukemia (92) and diffuse large B cell lymphoma (93) — they have shown mixed results in targeting solid cancers.”
Ho, J., Wang, L., Liu, Y., Ba, M., Yang, J., Zhang, X., Chen, D., Lu, P., & Li, J. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.03.007 · Cited by 65
Bachiller, M., Pérez-Amill, L., Battram, A. M., Carné, S. C., Najjar, A. M., Verhoeyen, E., Juan, M., Urbano-Ispizúa, Á., & Martín-Antonio, B. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002866 · Cited by 64
Emerging CAR T Cell Strategies for the Treatment of AML
Vishwasrao, P., Li, G., Boucher, J. C., Smith, D. L., & Hui, S. K. (2022) · Cancers · doi:10.3390/cancers14051241 · Cited by 64
“Currently, there are five FDA-approved CAR-T cell therapies: Tisagenlecleuel [1,2] (KYMRIAH; Novartis), Axicabtagene ciloleucel [3,4] (YESCARTA, Kite Pharma, Gilead Science), Brexucabtagene autoleucel (TECARTUS; Kite Pharma), l Isocabtagene maraleucel (BREYANZI; Juno Therapeutics, Inc.”
BackgroundGenetic therapeutic advancements for Dravet Syndrome
Chilcott, E. M., Diaz, J. F. A., Bertram, C., Berti, M., & Karda, R. (2022) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2022.108741 · Cited by 62
Rethinking cancer targeting strategies in the era of smart cell therapeutics
Allen, G. M., & Lim, W. A. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00505-x · Cited by 67
Prospects and challenges of CAR-T cell therapy combined with ICIs
Lv, Y., Luo, X., Xie, Z., Qiu, J.-Y., Yang, J., Deng, Y., Long, R., Tang, G., Zhang, C., & Zuo, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1368732 · Cited by 66
A collagenase nanogel backpack improves CAR-T cell therapy outcomes in pancreatic cancer
Zhao, Z., Li, Q., Qu, C., Jiang, Z., Jia, G., Lan, G., & Luan, Y. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01924-1 · Cited by 69
“Chimeric antigen receptor (CAR) T cell therapy is a groundbreaking treatment modality in haematological malignancy 1–3 .”
Systematic discovery of CRISPR-boosted CAR T cell immunotherapies
Datlinger, P., Pankevich, E. V., Arnold, C. D., Pranckevicius, N., Lin, J., Romanovskaia, D., Schaefer, M., Piras, F., Orts, A.-C., Nemc, A., et al. (2025) · Nature · doi:10.1038/s41586-025-09507-9 · Cited by 70
Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell Killing
Lemoine, J., Ruella, M., & Houot, R. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1559 · Cited by 68
Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells ‘off the shelf’?
DiNofia, A. M., & Grupp, S. A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00485-1 · Cited by 65
Self-citationTasian, S. K. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718774268 · Cited by 59
Cardiotoxicity of Contemporary Anticancer Immunotherapy
Dalbo, N., Patel, R. P., Parikh, R. B., Shah, S. P., Guha, A., Dani, S. S., & Ganatra, S. (2020) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-020-00867-1 · Cited by 64
Stein-Merlob, A. F., Rothberg, M. V., Holman, P., & Yang, E. H. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01440-3 · Cited by 62
Cheng, E. L., Cardle, I. I., Kacherovsky, N. A., Bansia, H., Wang, T., Zhou, Y., Raman, J., Yen, A., Gutierrez, D., Salipante, S. J., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c05349 · Cited by 62
Current Progress of CAR-NK Therapy in Cancer Treatment
Pang, Z., Wang, Z., Li, F., Feng, C., & Mu, X. N. (2022) · Cancers · doi:10.3390/cancers14174318 · Cited by 61
“Long-term survival studies of CAR-T cell therapy have shown that some patients relapse within one year post treatment [27,30].”
BackgroundKantarjian, H. M., Haddad, F., Jain, N., Sasaki, K., Short, N. J., Loghavi, S., Kanagal‐Shamanna, R., Jorgensen, J. L., Khouri, I. F., Kebriaei, P., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01444-2 · Cited by 60
Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology
Youssef, E. M., Fletcher, B., & Palmer, D. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1527600 · Cited by 75
Toward the potential cure of leukemias in the next decade
Kantarjian, H. M., Keating, M. J., & Freireich, E. J. (2018) · Cancer · doi:10.1002/cncr.31669 · Cited by 56
“The estimated 1-year survival rate was 60%.(131) In a second study reporting the long-term experience with CD19–CAR-T cells from Memorial Sloan Kettering,”
Background
Metadata
- Authors
- Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K., Davis, K. L., Martin, P. L., Nemecek, E. R., Yanik, G. A., Peters, C., Baruchel, A., Boissel, N., Mechinaud, F., Balduzzi, A., Krueger, J., June, C. H., Levine, B. L., Wood, P., Taran, T., Leung, M., Mueller, K. T., Zhang, Y., Sen, K., Lebwohl, D., Pulsipher, M. A., & Grupp, S. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Oslo University Hospital (NO)
- Hospital Sant Joan de Déu Barcelona (ES)
- University of Minnesota (US)
- Children's Mercy Hospital (US)
- From the Departments of Pediatrics (S.L.M., S.A.G.) and Pathology and Laboratory Medicine (C.H.J., B.L.L.), Perelman School of Medicine, and Abramson Cancer Center (C.H.J., B.L.L.), University of Pennsylvania, and the Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia (S.L.M., S.A.G.) — all in Philadelphia; the Department of Pediatrics and Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern...
- Royal Children's Hospital (AU)
- University of Southern California (US)
- ORCID
- Maude, Shannon L.
- Laetsch, Theodore W.
- Buechner, Jochen
- Rives, Susana
- Boyer, Michael
- Bittencourt, Henrique
- Bader, Peter
- Verneris, Michael R.
- Stefanski, Heather E.
- Qayed, Muna
- Hiramatsu, Hidefumi
- Davis, Kara L.
- Martin, Paul L.
- Nemecek, Eneida R.
- Yanik, Gregory A.
- Peters, Christina
- Boissel, Nicolas
- Mechinaud, Francoise
- Balduzzi, Adriana
- Krueger, Joerg
- June, Carl H.
- Levine, Bruce L.
- Zhang, Yiyun
- Lebwohl, David
- Pulsipher, Michael A.
- Grupp, Stephan A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-02
- Volume
- 378
- Issue
- 5
- Pages
- 439-448
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5996391
- OpenAlex
- W2787301955
- Cited by
- 5,735
- References
- 24
- Citations by year
- 2026: 573 · 2025: 671 · 2024: 734 · 2023: 730 · 2022: 784 · 2021: 788 · 2020: 706 · 2019: 496 · 2018: 242
- FWCI
- 207.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tisagenlecleucel, CAR T-cell therapy, anti-CD19, B-cell acute lymphoblastic leukemia, relapsed/refractory leukemia, pediatric and young adult patients, complete remission, minimal residual disease, event-free survival, overall survival, cytokine release syndrome, neurological adverse events, CAR T cell persistence, tocilizumab, treatment toxicity
- MeSH terms
- Adolescent, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Female, Humans, Infusions, Intravenous, Male, Receptors, Antigen, T-Cell, Remission Induction, Survival Analysis, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.